Nuvalent, Inc. (NUVL): Price and Financial Metrics


Nuvalent, Inc. (NUVL): $9.44

0.27 (+2.94%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NUVL to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

NUVL Stock Price Chart Interactive Chart >

Price chart for NUVL

NUVL Price/Volume Stats

Current price $9.44 52-week high $40.82
Prev. close $9.17 52-week low $7.09
Day low $8.89 Volume 106,800
Day high $9.67 Avg. volume 168,415
50-day MA $10.98 Dividend yield N/A
200-day MA $19.06 Market Cap 456.08M

Nuvalent, Inc. (NUVL) Company Bio


Nuvalent, Inc., a preclinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor, designed to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors; and NVL-655, a brain-penetrant ALK-selective inhibitor, designed to inhibit ALK fusions that express the normal ALK kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to first, second, and third generation ALK inhibitors. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.


NUVL Latest News Stream


Event/Time News Detail
Loading, please wait...

NUVL Latest Social Stream


Loading social stream, please wait...

View Full NUVL Social Stream

Latest NUVL News From Around the Web

Below are the latest news stories about Nuvalent Inc that investors may wish to consider to help them evaluate NUVL as an investment opportunity.

Nuvalent Appoints Emily Drabant Conley, PhD, to Board of Directors

Nuvalent, Inc. (Nasdaq: NUVL), a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Emily Drabant Conley, Ph.D., Chief Executive Officer of Federation Bio, to its Board of Directors.

Yahoo | February 3, 2022

Nuvalent begins dosing in phase 1/2 trial of NVL-520 for solid tumors, lung cancer

No summary available.

Seeking Alpha | January 7, 2022

Nuvalent Announces First Patient Dosed in ARROS-1 Phase 1/2 Clinical Trial of NVL-520, its Novel ROS1-selective Inhibitor

Nuvalent, Inc. (Nasdaq: NUVL), a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that the first patient has been dosed in ARROS-1, its Phase 1/2 clinical trial evaluating NVL-520 in patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) and other advanced solid tumors. NVL-520, Nuvalent's lead product candidate, is a novel ROS1-selective inhibitor designed to address the clinical challenges of emergent t

Yahoo | January 7, 2022

Nuvalent to Present at the 40th Annual J.P. Morgan Healthcare Conference

Nuvalent, Inc. (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 11:15 a.m. ET.

Yahoo | January 4, 2022

Nuvalent (NASDAQ:NUVL) Stock Price Down 2.5%

Nuvalent Inc (NASDAQ:NUVL)’s share price was down 2.5% during trading on Tuesday . The stock traded as low as $19.06 and last traded at $19.06. Approximately 613 shares changed hands during mid-day trading, a decline of 99% from the average daily volume of 98,252 shares. The stock had previously closed at $19.54. Separately, Zacks Investment […]

Transcript Daily | December 23, 2021

Read More 'NUVL' Stories Here

NUVL Price Returns

1-mo -16.39%
3-mo -39.14%
6-mo -54.53%
1-year N/A
3-year N/A
5-year N/A
YTD -50.42%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4845 seconds.